DAVION HEALTHCARE PLC CONFIRMS EXPECTED NASDAQ TRADING DATE AND ANNOUNCES NEW EXECUTIVE LEADERSHIP AND OPERATING STRUCTURE
Davion Healthcare confirmed its ordinary shares are expected to begin trading on the Nasdaq Global Market on Thursday, October 22, 2026, under ticker DAVI. Glenn Williams will become CEO and Jeremy North COO upon commencement of trading, with current CEO Jack Kaye moving to Chairman and Sir Eric Peacock stepping down to Non-Executive Director. A new Operational Directorate will run commercialisation, operations and M&A execution. The company's flagship product is BreastCheck, an FDA-registered at-home breast health screening test, with a pipeline including FootFlow, Testic and ThermaDerm.
Key figures
- Nasdaq trading start
- 2026-10-22
- Acquisition financing
- £30 million five-year senior secured bond via Davion Healthcare Finance Ltd
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.